Axsome Therapeutics, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 30 May 2026 | Pharmaceuticals | Market Cap: ₹12.0K Cr
- AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from Major Depressive Disorder (MDD) and Alzheimer’s disease (AD) agitation indications. - Focus currently remains on revenue growth as the top priority.
From Axsome Therapeutics, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Price
₹232.83
Market Cap
₹12.0K Cr
P/E Ratio
39.8
Revenue Rank
Margin Rank
How does Axsome Therapeutics, Inc. rank in Pharmaceuticals?
Compare Axsome Therapeutics, Inc. against every Pharmaceuticals company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from Major Depressive Disorder (MDD) and Alzheimer’s disease (AD) agitation indications.
- →Continued growth expected for AUVELITY driven by expanded sales force (~630 reps) targeting 68,000 HCPs across multiple specialties and care settings.
- →Anticipated strong uptake from ongoing awareness campaigns, improved payer coverage (86% total coverage), and early frontline prescribing shifts.
- →SUNOSI revenue growing steadily, with 16% year-over-year growth in Q1 2026 and stable payer coverage (~83%).
- →SYMBRAVO showing 36% growth compared to Q4 2025, with sales force expansion and increasing primary care use.
- →Overall, revenue growth anticipated to continue, with operating leverage improving as top-line revenue outpaces operating expense growth.
- →Cautious near-term forecasting on Alzheimer’s Disease Agitation (ADA) uptake, but belief in transitory Q1 seasonality and robust longer-term ramp.
📈 Profitability & Margins
Rank 3- →Focus currently remains on revenue growth as the top priority.
- →Next goals after revenue growth are achieving cash flow positivity, followed by profitability.
- →Operating leverage expected as top-line revenue growth is anticipated to outpace operating expenses.
- →SG&A expenses likely to increase in Q2 2026 but at a slower rate, then level out.
- →Peak sales guidance: AUVELITY at least $8 billion, SUNOSI $300-$500 million, SYMBRAVO $500 million to $1 billion.
- →Expansion in sales force and market access expected to support continued strong revenue growth.
- →AUVELITY’s approval in two indications provides a clear line of sight to significant market potential.
- →IRA negotiations potentially impacting AUVELITY from 2031 onwards; current $8 billion peak estimate accounts for this.
- →Profitability is a mid-term goal, following revenue growth and cash flow positivity.
🏗️ Capital Expenditure Plans
Yes- →No specific details on current or future capital expenditures (capex) or strategic investments are explicitly mentioned in the document.
- →The company is primarily focused on commercial execution, including expanding their sales force and marketing activities (e.g., AUVELITY and SYMBRAVO launches).
- →Investment efforts appear directed towards clinical development with several Phase III trials planned or ongoing (e.g., AXS-12, AXS-05, Solriamfetol programs, AXS-20 in late-stage development).
- →Acquisition history noted (e.g., SUNOSI acquisition), but current focus remains on pipeline and commercialization rather than new acquisitions.
- →Expansion of commercial infrastructure includes increased sales teams for SYMBRAVO and AUVELITY, indicating operational investments.
- →Cash balance of $305 million expected to fund operations through to cash flow positivity, suggesting no major unannounced capital projects at this time.
💰 Fundraising & Capital Structure
No information- →The provided document (pages 4-15) does not mention any current or planned fundraising activities through debt or equity.
- →The focus is on commercial execution, product launches (AUVELITY in Alzheimer’s agitation), pipeline progress, and business development.
- →Financial discussions highlight revenue growth, operating leverage, and managing SG&A expenses but do not reveal plans for raising capital.
- →Past acquisitions (e.g., SUNOSI) are referenced but no new fundraising strategies are detailed.
- →Long-term financial goals include achieving cash flow positivity and profitability, indicating attention to financial discipline rather than immediate capital raises.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Pharmaceuticals this season
- Elanco Animal Health Incorporated (Q2 FY26)
Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S
- Jazz Pharmaceuticals plc (Q2 FY26)
Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo
- Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7
- Royalty Pharma plc (Q2 FY26)
Royalty Pharma plc Q2 FY26 quarterly results analysis. Royalty Pharma expects strong low-volatility top and bottom line growth through 2030 and beyond, driven b
Frequently Asked Questions
What were Axsome Therapeutics, Inc. Q2 FY26 results?
- AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from Major Depressive Disorder (MDD) and Alzheimer’s disease (AD) agitation indications. - Focus currently remains on revenue growth as the top priority.
What is Axsome Therapeutics, Inc. share price analysis?
Axsome Therapeutics, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 39.8 with a market cap of $11,981. Investors should review the full earnings analysis for detailed insights.
Is Axsome Therapeutics, Inc. planning capital expenditure?
- No specific details on current or future capital expenditures (capex) or strategic investments are explicitly mentioned in the document.
Keep Axsome Therapeutics, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.